{"disease":{"id":"head-and-neck-hnscc","name":"head and neck hnscc"},"drugs":{"marketed":[{"drug_id":"immuno-oncology-io","indication_name":"Head and Neck Squamous Cell Carcinoma (HNSCC)","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Immuno-oncology (IO)","generic_name":"immuno-oncology-io","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"Not specified","drug_class":"Not specified","quality_score":45,"revenue":"1301","mechanism":""},{"drug_id":"pf-06865571","indication_name":"Head and Neck Squamous Cell Carcinoma (HNSCC) in adults","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""},{"drug_id":"pf-06865571","indication_name":"Head and Neck Squamous Cell Carcinoma (HNSCC) in adults in combination with pembrolizumab","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pf-06865571","generic_name":"pf-06865571","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"PD-1/PD-L1 pathway","drug_class":"Monoclonal antibody","quality_score":45,"revenue":null,"mechanism":""}],"pipeline":[],"offLabel":[],"totalMarketed":3,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05176483","title":"Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":1314,"lead_sponsor_name":"Exelixis","has_results":false},{"nct_id":"NCT06885424","title":"A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) Products","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":400,"lead_sponsor_name":"A2 Biotherapeutics Inc.","has_results":false},{"nct_id":"NCT07512921","title":"Matching Primary Tumor and Blood Gene Expression Analysis of HPV-negative Squamous Head and Neck Cancers","phase":"","overall_status":"RECRUITING","enrollment_count":300,"lead_sponsor_name":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","has_results":false},{"nct_id":"NCT06606028","title":"Tumor-Informed ctDNA Testing for MRD Following Treatment of Squamous Cell Carcinoma","phase":"","overall_status":"RECRUITING","enrollment_count":250,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT06682793","title":"A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":240,"lead_sponsor_name":"A2 Biotherapeutics Inc.","has_results":false},{"nct_id":"NCT04215978","title":"Safety and Preliminary Effectiveness of BGB-A445 in Combination With Tislelizumab in Participants With Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":204,"lead_sponsor_name":"BeiGene","has_results":false},{"nct_id":"NCT07190755","title":"Impact of Patient-Reported Outcomes for Symptom Monitoring in Patients Followed for Head and Neck Squamous Cell Carcinoma (HNSCC)","phase":"NA","overall_status":"RECRUITING","enrollment_count":192,"lead_sponsor_name":"Centre Henri Becquerel","has_results":false},{"nct_id":"NCT04799054","title":"A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"TERMINATED","enrollment_count":188,"lead_sponsor_name":"Ascendis Pharma Oncology Division A/S","has_results":false},{"nct_id":"NCT07371897","title":"Toripalimab ± Chemo as Neoadjuvant Therapy in LA-HNSCC: A Phase III Trial","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":154,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT07471009","title":"Development of Patient Derived Xenografts (PDXs) and Analysis of Tyrosine Kinase Receptor Expression in Patients With Squamous Cell Head and Neck Cancer (HNSCC) to Study Resistance Mechanisms Induced by Standard Therapy","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":120,"lead_sponsor_name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","has_results":false},{"nct_id":"NCT06769698","title":"A Study to See if Giving Fianlimab and Cemiplimab Together is Better Than Cemiplimab Alone at Treating Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":120,"lead_sponsor_name":"Regeneron Pharmaceuticals","has_results":false},{"nct_id":"NCT07423078","title":"Window of Opportunity in Preserving Laryngeal Function Trial","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":87,"lead_sponsor_name":"Matthew Spector","has_results":false},{"nct_id":"NCT06366945","title":"Tirelizumab in Combination With Carboplatin and Polymeric Micellar Paclitaxel for Neoadjuvant Therapy in cN+ HNSCC","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":85,"lead_sponsor_name":"Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University","has_results":false},{"nct_id":"NCT05827614","title":"Study of the CHK1 Inhibitor BBI-355, an ecDNA-directed Therapy (ecDTx), and the RNR Inhibitor BBI-825, in Subjects With Tumors With Oncogene Amplifications","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":85,"lead_sponsor_name":"Boundless Bio, Inc.","has_results":false},{"nct_id":"NCT06814067","title":"Phase II Multi-centered Study of Perioperative Ivonescimab Versus Pembrolizumab Combined with Standard of Care (SOC) in Patients with Resectable, Locally Advanced Head and Neck Squamous Cell Carcinoma","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":80,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT04080804","title":"Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":80,"lead_sponsor_name":"Dan Zandberg","has_results":false},{"nct_id":"NCT03746431","title":"A Phase 1 Study of [225Ac]-FPI-1434 Injection","phase":"PHASE1","overall_status":"TERMINATED","enrollment_count":78,"lead_sponsor_name":"Fusion Pharmaceuticals Inc.","has_results":false},{"nct_id":"NCT03422536","title":"Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":78,"lead_sponsor_name":"University of Arizona","has_results":true},{"nct_id":"NCT06869473","title":"Cetuximab Plus Platinum and Taxane-based Chemotherapy, Followed by Avelumab and Cetuximab, as First-line Treatment for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC) Patients With a PD-L1 Combined Positive Score (CPS)≥1≤19.","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":67,"lead_sponsor_name":"Gruppo Oncologico del Nord-Ovest","has_results":false},{"nct_id":"NCT02684253","title":"Screening Trial of Nivolumab With Image Guided, Stereotactic Body Radiotherapy (SBRT) Versus Nivolumab Alone in Patients With Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":65,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":true},{"nct_id":"NCT02383927","title":"Phase II Study of Tipifarnib in Squamous Head and Neck Cancer With HRAS Mutations","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":63,"lead_sponsor_name":"Kura Oncology, Inc.","has_results":true},{"nct_id":"NCT05859074","title":"A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":56,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT03276819","title":"A Clinical and Biological Umbrella Protocol for Smoker or Non-smoker Patients With OPML or HNSCC","phase":"NA","overall_status":"TERMINATED","enrollment_count":53,"lead_sponsor_name":"Centre Leon Berard","has_results":false},{"nct_id":"NCT06630780","title":"Reduction of Postoperative Radiotherapy in Head and Neck Squamous Cell Carcinoma","phase":"NA","overall_status":"RECRUITING","enrollment_count":50,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT04815720","title":"Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":49,"lead_sponsor_name":"Vaccinex Inc.","has_results":false},{"nct_id":"NCT05249426","title":"A Study to Test Whether Different Combinations of BI 765063, Ezabenlimab, Chemotherapy, Cetuximab, and BI 836880 Help People With Head and Neck Cancer or Liver Cancer","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":48,"lead_sponsor_name":"Boehringer Ingelheim","has_results":false},{"nct_id":"NCT06736379","title":"Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":41,"lead_sponsor_name":"VLP Therapeutics","has_results":false},{"nct_id":"NCT06839014","title":"Exercise Therapy in Head and Neck Squamous Cell Carcinoma (HNSCC)","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":40,"lead_sponsor_name":"Our Lady of the Lake Hospital","has_results":false},{"nct_id":"NCT04722523","title":"A Study of Cemiplimab With Chemotherapy and Immunotherapy in People With Head and Neck Cancer","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":40,"lead_sponsor_name":"Memorial Sloan Kettering Cancer Center","has_results":false},{"nct_id":"NCT04284540","title":"Hypofractionated Radiotherapy in Elderly Patients With Head & Neck Squamous Cell Carcinoma","phase":"NA","overall_status":"COMPLETED","enrollment_count":37,"lead_sponsor_name":"Icahn School of Medicine at Mount Sinai","has_results":false},{"nct_id":"NCT05980000","title":"Ramucirumab and Pembrolizumab vs Pembrolizumab Monotherapy in PD-L1 Positive Head and Neck Squamous-Cell Carcinoma","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":37,"lead_sponsor_name":"Washington University School of Medicine","has_results":false},{"nct_id":"NCT06102447","title":"Efficacy and Safety of Netupitant and Palonosetron Hydrochloride Capsules in Preventing Nausea and Vomiting Induced by Radiochemotherapy in Head and Neck Squamous Cell Carcinoma","phase":"NA","overall_status":"UNKNOWN","enrollment_count":36,"lead_sponsor_name":"Sichuan Cancer Hospital and Research Institute","has_results":false},{"nct_id":"NCT03944915","title":"De-Escalation Therapy for Human Papillomavirus Negative Disease","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":35,"lead_sponsor_name":"University of Chicago","has_results":true},{"nct_id":"NCT07465276","title":"Neoadjuvant Ficerafusp Alfa With Pembrolizumab in Resectable SCC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":32,"lead_sponsor_name":"Dana-Farber Cancer Institute","has_results":false},{"nct_id":"NCT06530914","title":"A Phase II Study of MRG003 Injection Combined With Pucotenlimab Injection ± Cisplatin Injection in the Neoadjuvant Treatment Locally Advanced EGFR-positive Head and Neck Squamous Cell Carcinoma","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":30,"lead_sponsor_name":"Lei Liu","has_results":false},{"nct_id":"NCT07149207","title":"Intraoperative Molecular Imaging Using ICG for Head and Neck Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":30,"lead_sponsor_name":"Medical University of South Carolina","has_results":false},{"nct_id":"NCT06714266","title":"Trilaciclib in Preventing Hematopoietic Suppression in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":30,"lead_sponsor_name":"Shandong Cancer Hospital and Institute","has_results":false},{"nct_id":"NCT06673693","title":"Tislelizumab Combined With SBRT for the Treatment of Head and Neck Squamous Cell Carcinoma","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":24,"lead_sponsor_name":"Sun Yat-sen University","has_results":false},{"nct_id":"NCT04220866","title":"Study of Intratumoral (IT) Ulevostinag (MK-1454) in Combination With Intravenous (IV) Pembrolizumab (MK-3475) Compared to IV Pembrolizumab Alone as the First Line Treatment of Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) (MK-1454-002)","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":18,"lead_sponsor_name":"Merck Sharp & Dohme LLC","has_results":true},{"nct_id":"NCT04606940","title":"Study of Circulating Tumor DNA (ctDNA) Kinetics in Immuno-oncology (IO-KIN)","phase":"","overall_status":"COMPLETED","enrollment_count":18,"lead_sponsor_name":"University Health Network, Toronto","has_results":false},{"nct_id":"NCT03735628","title":"An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":16,"lead_sponsor_name":"Bayer","has_results":false},{"nct_id":"NCT06052839","title":"Pulsed Dose Chemotherapy Plus Pembrolizumab in Recurrent/Metastatic HNSCC","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":15,"lead_sponsor_name":"Dan Zandberg","has_results":false},{"nct_id":"NCT05068102","title":"A Study to Test How BI 765063 and BI 770371 Are Taken up in Tumours of People With Different Types of Advanced Cancer Who Are Also Taking Ezabenlimab","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":14,"lead_sponsor_name":"Boehringer Ingelheim","has_results":false},{"nct_id":"NCT07457281","title":"GV20-0251 and Sintilimab for Neoadjuvant Treatment of Resectable Head and Neck Squamous Cell Carcinoma: A Single-Arm Study","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":9,"lead_sponsor_name":"West China Hospital","has_results":false},{"nct_id":"NCT03811652","title":"A Multiple Ascending Dose Study of MEDI7247 in Advanced or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":8,"lead_sponsor_name":"MedImmune LLC","has_results":false},{"nct_id":"NCT03268993","title":"Effects of Avmacol® in the Oral Mucosa of Patients Following Curative Treatment for Tobacco-related Head and Neck Cancer","phase":"NA","overall_status":"COMPLETED","enrollment_count":6,"lead_sponsor_name":"University of Pittsburgh","has_results":false},{"nct_id":"NCT04849377","title":"RBD-HPV: Risk-Based De-Intensification for HPV+ HNSCC","phase":"PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Icahn School of Medicine at Mount Sinai","has_results":false},{"nct_id":"NCT03114280","title":"Pembrolizumab and Induction Chemotherapy in Head and Neck Squamous Cell Carcinoma (PICH Study)","phase":"PHASE1, PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"Centre Antoine Lacassagne","has_results":false}],"total":48},"guidelines":[],"source":"Drug Landscape verified database"}